Cardiac AL Amyloidosis (RCD code: III-3A.2a)

Olga Kruszelnicka, Mark Chmiela, Małgorzata Raźny, Bernadeta Chyrchel, Jolanta Świerszcz, Andrzej Surdacki, Jadwiga Nessler

Full Text:



Primary systemic amyloidosis (AL amyloidosis) is the most common subtype of amyloidosis in developed countries. Amyloid fibrils deposition results from an abnormal secondary structure of immunoglobulin light chains produced by a plasma cell clone. The most common accompanying plasma cell dyscrasia is monoclonal gammopathy of undetermined significance, while multiple myeloma coexists in only 10–15% of patients. The kidneys and the heart are the most frequently affected organs. Patients usually present with concentric left ventricular concentric thickening displaying a restrictive filling pattern with well-preserved systolic function. Clinical suspicion of AL amyloidosis should be raised in older adults and elderly patients with diastolic heart failure accompanied by heavy proteinuria, upon detection of thick-walled heart on echocardiography with low-voltage QRS on ECG (“red-flags” for amyloidosis”), in non-diabetic subjects with peripheral neuropathy or autonomic neuropathy, commonly with severe postural hypotension. Classical clinical stigmata, i.e. periorbital purpura, macroglossia, carpal tunnel syndrome, are not frequent (10–20%) but can guide diagnosis. In the presence of typical echocardiographic features recommended diagnostic steps include identification of monoclonal gammopathy (serum and urine immunofixation and serum free light-chain kappa to lambda ratio) and confirmation of amyloid deposition, preferentially in a non-cardiac tissue such as periumbilical fat or minor salivary glands. Bone marrow biopsy, serum calcium assay and skeletal survey are mandatory to exclude multiple myeloma. Prognosis is mainly dependent on cardiac involvement, being determined by cardiac biomarkers and the difference between involved and uninvolved light chains. Intensive chemotherapy is the therapy of choice in intermediate-risk patients with AL amyloidosis. An improved overall survival was reported in patients with a complete haematological response and an adequate cardiac response, especially a fall in circulating levels of B-type natriuretic peptides. JRCD 2016; 2 (8): 245–253


rare disease, AL amyloidosis; restrictive cardiomyopathy; monoclonal gammopathy; plasma cell dyscrasia


Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141–157.

Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006; 1: 1331–1341.

Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 50: 2101–2110.

Liszniański P, Nowak P, Nowak J. Patient with multiple myeloma and suspected cardiac amyloidosis. J Rare Cardiovasc Dis 2015; 2: 56–59.

Desport E, Bridoux F, Sirac C, et al. AL amyloidosis. Orphanet J Rare Dis 2012; 7: 54.

Gertz M, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005; 79: 319–328.

Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499–504.

Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013; 121: 5124–5130.

Katzmann J, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437–1444.

Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047–2060.

Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95: 535–537.

Granstam S-O, Rosengren S, Vedin O, et al. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization. Amyloid 2013; 20: 27–33.

Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004; 43: 410–415.

Namdar M, Steffel J, Jetzer S, et al. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012; 109: 587–593.

Porciani MC, Lilli A, Perfetto F, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid 2009; 16: 63–70.

Ho CY, Solomon SD. A clinician’s guide to tissue Doppler imaging. Circulation 2006; 113: e396–e398.

Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012; 1: e000 364.

Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97: 75–84.

Dandel M, Lehmkuhl H, Knosalla C, et al. Strain and strain rate imaging by echocardiography – basic concepts and clinical applicability. Curr Cardiol Rev 2009; 5: 133–148.

Abraham TP, Dimaano VL, Liang H-Y. Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation 2007; 116: 2597–2609.

Koyama J, Ray-Sequin P, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003; 107: 2446–2452.

Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022–1030.

Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155–164.

Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? I Int Med 2015; 278: 126–144.

Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012; 87: 465–471.

Palladini G, Dispenzieri A, Gertz M, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541–4549.

Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440–2445.

Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351–1358.

Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol 2014; 89: 1132–1140.

Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016; 387: 2641–2654.

Seldin DC, Anderson JJ, Skinner M, et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006; 108: 3945–3947.

Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865–873.

Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010; 52: 347–361.

Kumar S, Dispenziera A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989–995.

Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation 2015; 132: 1570–1579.

Palladini G1, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854–3858.

Leung N, Glavey SV, Kumar S, et al. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica 2013; 98: 988–992.

Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol 2013; 22: 189–194.

Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165: 1425–1429. 40. Fine NM, Arruda-Olson AM, Dispenzieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 2014; 113: 1723–1727.



  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659